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Introduction / objectives
Lupoid leishmaniasis (LCL) is a rare, face disfiguring,
treatment resistant complication which has responded
to the expensive photodynamic therapy in 5 patients in
Iran [ F. Ghaffarifar et al. La Rev. de la Méditerranée
orientale Vol. 12 No. 6, 2006]. Here we report 5 cases,-
photodocumented as best as we could under the actually
disastrous conditions of Afghan Health Care,- treated
with 0.045% DAC N-055 [German Drug Codex, 1990],
which is split into
1O2 and 2NaClO2 after 360 nm light
exposure and reacts as chlorite in iodometry.
Methods
The faces of 5 patients with a CL anamnesis and clini-
cally diagnosed as lupoïd CL were treated daily for the
first week with 0.045 % DAC N-055 prepared in basic
crème DAC B-20 under occlusive dressings, thereafter
the patients were instructed to treat themselves with
this hydrophilic crème and were told to show up as out-
door patients at least once per fortnight. Pharmaceutical
chlorite, NaClO2 [monograph DAC N-055] is O2
enriched due to its Na2Cl2O6 content, formerly called
TCDO, (NaClO2)4·O2, which fights viral, bacterial or
parasitic tissue infections and promotes wound granula-
tion even in radiogenic ulcers [http://www-pub.iaea.org/
mtcd/publications/pdf/te_1300_web.pdf].
Results
1 patient was lost, 4 patients healed completely with-
out scarring and with excellent cosmetic results (see
photos!), 3 within 3 months, 1 after 10 months because
of an additional severe eczema. There were no clinical
signs of recurrence, one patient was followed for
6 years.
Conclusion
The low treatment costs for such excellent cosmetic
results are appropriate for poor Afghan patients.
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